期刊
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fbioe.2022.1000873
关键词
microbiota; microbiome engineering; human health; clinical trials; engineered bacteria
资金
- EPSRC [EP/W004674/1]
- EPSRC studentship [2505625]
- European Research Council (ERC) under the European Union [770835]
- Wellcome Trust [209409/Z/17/Z]
- Wellcome Trust [209409/Z/17/Z] Funding Source: Wellcome Trust
- European Research Council (ERC) [770835] Funding Source: European Research Council (ERC)
The human microbiota is associated with many diseases, and microbiome engineering methods aim to modify the composition and function of the microbiota for therapeutic purposes. Clinical studies on engineered microorganisms have shown promising progress in recent years.
The human microbiota is implicated in many disease states, including neurological disorders, cancer, and inflammatory diseases. This potentially huge impact on human health has prompted the development of microbiome engineering methods, which attempt to adapt the composition and function of the human host-microbiota system for a therapeutic purpose. One promising method is the use of engineered microorganisms that have been modified to perform a therapeutic function. The majority of these products have only been demonstrated in laboratory models; however, in recent years more concepts have reached the translational stage. This has led to an increase in the number of clinical trials, which are designed to assess the safety and efficacy of these treatments in humans. Within this review, we highlight the progress of some of these microbiome engineering clinical studies, with a focus on engineered live biotherapeutic products.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据